NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Wow—this really is a gem and a breakthrough… the more I read and compare other trials, the more DCVax-L shines — The methylated subgroup, older group, recurrent group, the incredible tails…the data have great meaning and invaluable implications to the field of immunotherapy in oncology if anyone really looks at it …and this is just the tip of the iceberg of its possible uses in other cancers…

Just one of many examples that caught my eye was from the recent Nivolumab GBM trial JAMA article:

“Nearly all patients experience recurrence following standard-of-care surgical resection, radiotherapy, and temozolomide. Treatment options at recurrence are limited, and no therapy has prolonged overall survival (OS) in this setting, which underscores the need for novel therapeutic interventions in this patient population”

DCVax-L had an amazing impact on the OS in the recurrent group and an astonishing tail.